A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

Exclusion Criteria

• •All Participants
• •History or presence of alcohol or drug abuse within the past 1 year prior to dosing.
• •Female participant with a positive pregnancy test at the screening visit or at check-in or who is lactating or breastfeeding.
• •Positive urine or breath alcohol results at screening or check-in. Unable to refrain from or anticipates the use of any drugs.
• •Positive results for HIV at screening.
• •Donation of blood or significant blood loss within 56 days prior to dosing.
• •Plasma donation within 7 days prior to dosing.
• •Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to dosing.
• •Participants with Mild and Moderate HI
• •With the exception of HI, history or presence of clinically significant medical or psychiatric condition or disease, or any illness that might confound the results of the study or poses an additional risk to the participant by their participation in the study.
• •History of severe complications of liver disease within the preceding 3 months of screening.
• •Primary biliary cholangitis or biliary obstruction at screening.
• •Fluctuating or rapidly deteriorating hepatic function from screening until prior to dosing.
• •History of liver or other solid organ transplantation.
• •Requires paracentesis more often than 2 times per month.
• •Transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting within 90 days prior to screening.
• •Received antiviral and/or immune modulating therapy for active hepatitis infection within 90 days prior to dosing.
• •Diabetic participants with HbA1c \> 8.5% at screening.
• •Positive for HBsAg or HBcAb and has positive hepatitis B virus DNA at screening.
• •Positive for HCV and has a detectable HCV viral load at screening.
• •Participants with Normal Hepatic Function
• •History or presence of clinically significant medical or psychiatric condition or disease, or any illness that might confound the results of the study or poses an additional risk to the participant by their participation in the study.
• •Alcohol consumption \> 14 drinks per week for males (7 for females) within 45 days of screening.
• •Positive result for HBsAg or HCV at screening.